Navigation Links
Liver fibrosis will be treated by a potential target
Date:10/16/2007

The outcome of hepatitis is either self recovery or its development into liver fibrosis or, further, liver cirrhosis. Liver fibrosis is the early pathological process of cirrhosis, which is considered a reversible, wound-healing response. Since no ideal drug is available for its therapy, liver fibrosis is currently considered to be a major worldwide health problem.

Previous studies have demonstrated that activin A is involved in hepatic fibrosis formation. However, the mechanism of the fibrotic process is not well understood. Activin receptor-interacting protein 2 (ARIP2) has been recently identified as a negative regulator of activin signal pathways. The fact that ARIP2 is highly expressed in the liver suggests that ARIP2 may participate in activin-induced anti-fibrosis in the liver.

A research article published on November 7 in the World Journal of Gastroenterology addresses this question. A research team led by Dr. ZH Liu from Jilin University spent more than five years researching ARIP2. The researchers used mouse Hepal-6 cells obtained from mouse a hepatoma cell line that had functions of hepatic parenchymal cells to investigate the effects of ARIP2 anti-fibrosis on the production of collagen type IV, which is a component of the extracellular matrix (ECM) in liver fibrosis.

One conclusion reported by the investigators is that the mode of expression regulation by various activators of signaling transduction, such as PMA, foskolin and LPS, has been characterized, and its negative effect on the production of collagen type IV revealed, using Hepal-6 cells.

An additional result was that the expression level of ARIP2 mRNA in the Hapel-6 cells was elevated 12 h after treatment with activin A and endotoxin LPS. Thus, it was concluded that ARIP2 participates in the negative feedback regulation of signal transduction in the late stage by affecting the expression of ActRIIA, which further suggests that ARIP2 might be a potential target for treatment of liver fibrosis induced by activin.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Blood Cells Capable of Regenerating Liver
2. Laboratory Testing Can Identify Risk of Pre-Term Labor and Delivery
3. Infant receives first bloodless liver transplant
4. Liver donors can thrive after transplant
5. Antibiotic induces liver damage in children with E.COLI infections.
6. The Effects Of Delaying A Delivery Questioned
7. Baby Lennox Gets Liver Transplant
8. Milk Thistle Not An Effective Cure For Liver Disease
9. Metronidazole Increases Risk Of Premature Deliveries.
10. Early delivery can prevent cancer
11. A new treatment for liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... ... 2017 , ... The StayWell Company and VUCA Health ... health risks, foster behavior change and improve health literacy among patients. VUCA Health, which ... demonstration of its video capability at StayWell booth 3443 during HiMSS. , The ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the world ... visit this week at HIMSS 2017 Conference & Exhibition. The event brings more ... will be featured in the conference’s Connected Health Experience section, an area specifically ...
(Date:2/20/2017)... ... ... a Population Health Software Company, is pleased to announce a move to a larger office ... the size of the previous location while bringing life back to a medical practice building ... are excited to expand our footprint to better serve our growing client base. We ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital ... A topping out ceremony on Friday marked the halfway point of construction and lifting ... in Fall 2018, will serve as a center for innovation aimed at finding new ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... Feb. 19, 2017   AC Group Inc. , ... ranking of vendors in the PMS/EHR healthcare marketplace, will ... system requirements to succeed in this ecosystem at HIMSS,17. ... together information obtained from over 200 ACOs, compared and ... and services companies that are providing different pieces of ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
Breaking Medicine Technology: